NasdaqGS - Delayed Quote USD

Valneva SE (VALN)

7.64 +0.10 (+1.32%)
At close: April 26 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Thomas Lingelbach President, CEO & Director 986.47k -- 1963
Mr. Peter Buhler Chief Financial Officer 599.49k -- 1971
Mr. Frederic Jacotot VP of Legal & IP, General Counsel, and Corporate Secretary 327.41k -- 1964
Mr. Franck Grimaud MBA Chief Business Officer 430.54k -- 1967
Dr. Juan-Carlos Jaramillo M.D. Chief Medical Officer 579.03k -- 1972
Ms. Dipal Patel Chief Commercial Officer 554.35k -- 1975
Mr. Vincent Dequenne Chief Operating Officer -- -- 1967
Mr. Joshua Drumm Ph.D. Vice President of Investor Relations -- -- --
Ms. Laetitia Bachelot-Fontaine VP of Global Communications & European Investor Relations -- -- --
Ms. Petra Pesendorfer Chief People Officer -- -- 1986

Valneva SE

6 rue Alain Bombard
Saint-Herblain, 44800
France
33 2 28 07 37 10 https://valneva.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
676

Description

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Corporate Governance

Valneva SE’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 9; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers

HLVX HilleVax, Inc.
12.79
+6.41%
 
LENZ LENZ Therapeutics, Inc.
15.72
+1.75%
 
GLUE Monte Rosa Therapeutics, Inc.
5.33
-2.20%
 
LYEL Lyell Immunopharma, Inc.
2.1700
-1.36%
 
ANAB AnaptysBio, Inc.
21.00
+11.29%
 
NBTX Nanobiotix S.A.
5.74
-1.03%
 
4XC1.F KalVista Pharmaceuticals, Inc.
9.60
+3.23%
 
4RY.DU Akeso Inc
5.65
+4.63%
 
FBIOP Fortress Biotech, Inc.
13.82
+2.83%
 
PEPG PepGen Inc.
11.93
+1.97%